Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

Table 7 Adverse events in 69 patients on Alirocumab 75 mg or Alirocumab 150 mg or Evolocumab 140¹ mg every 2 weeks, by entry statin intolerance group

	Statin tolerant, taking statin (n = 23)	Statin intolerant (n = 46)
	Follow up length	Follow up length
	25th, 50th, 75th %tile	25th, 50th, 75th %tile
	28, 39, 16 weeks	30, 40, 52 weeks
Flu-like symptoms	2 (9%)	8 (17%)
Respiratory tract infection /symptoms	1 (4%)	1 (2%)
Inject site reaction	1 (4%)
Fatigue	0	2 (4%)
Headache	0	2 (4%)
Urticaria /itchiness	0	2 (4%)
G.I. symptom	0	2 (4%)
Weight gain	1 (4%)	1 (2%)
Hair loss	0	1 (4%)
Any adverse events	5 (22%)	19 (41%)

ISSN: 1476-511X